诺健生物科技研发（苏州）有限公司是由美国富达生物科学研究启动基金投资，在中国专注于中枢神经系统药物开发的生物技术公司。诺健公司由经验丰富的管理团队领导，其科研人员在神经科学研究领域具有杰出的专业知识。公司核心技术来自于数位在神经科学领域卓有建树的创始人。公司的宗旨是综合利用创始人的前沿科学发现，独有动物模型，特有药物筛选平台，资深管理团队和中国优势，来开发创新型药物用于治疗多种中枢神经系统疾病, 包括自闭症，强迫症，老年痴呆症和抑郁症等。
Rugen Therapeutics, Inc. is a biotech company in China focusing on discovery & development of innovative medicine to address major unmet medical needs of patients worldwide with disorders of central nerve system, such as autism, bipolar & schizophrenia.
Founded in October 2010 by Prof. Guoping Feng from MIT, Prof. Zhigang He from Harvard and Dr. Jay Liu from AstraZeneca, Rugen is unique animal models, knowledge on disease mechanisms, enabling technology platform and strong financial support from Fidelity Bioscience. We are building a world-class company with cutting-edge technology and strong product pipeline for major CNS disorders, including autism, Alzheimer’s, bipolar, depression and schizophrenia.
地 址：江苏省苏州工业园区星湖街218号生物纳米科技园C19楼401室
邮政编码：215007
